Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effects of Micro-dose and Low-dose rhEpo on Mitochondrial Function and Cognition
NCT03093506Phase 1Completed
- Sponsor
- Bispebjerg and Frederiksberg Hospital
- Start
- Sep 2011
- Primary completion
- Dec 2011
- Modality
- Erythropoietins, Colony Stimulating Factors
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of epoetin beta in Mitochondriopathy and cognitive impairment (3 arms), sponsored by Bispebjerg and Frederiksberg Hospital. Primary endpoint: Maximal oxygen-flux at 4 weeks. Started Sep 2011; status: completed.
02
Drugs
epoetin beta
03
Conditions
Mitochondriopathycognitive impairment
Beyond the preview
Go deeper on NCT03093506.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03093506.